Related Experiment Videos
[Antithrombin III substitution in patients in shock]
Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1984
Summary
Antithrombin III (AT III) is crucial for heparin's anticoagulant effect. Low AT III levels significantly reduce heparin efficacy, while AT III substitution shortens disseminated intravascular coagulation (DIC) duration.
Area of Science:
- Biochemistry
- Hematology
Context:
- Disseminated intravascular coagulation (DIC) is a life-threatening condition characterized by abnormal activation of coagulation.
- Heparin is commonly used to manage DIC, but its efficacy is dependent on Antithrombin III (AT III) levels.
Purpose:
- To investigate the relationship between Antithrombin III (AT III) concentration, heparin efficacy, and AT III activity in patients with shock and DIC.
- To evaluate the impact of AT III substitution on the duration and outcomes of acute DIC.
Summary:
- Heparin's anticoagulant effect is significantly diminished when Antithrombin III (AT III) activity falls below 75% of normal levels, becoming negligible at 50%.
- AT III substitution in acute DIC patients led to a shorter duration of the condition (16-19 hours) compared to heparin alone (3.3 days).
- Increased consumption of AT III by coagulation proteases was suggested by differing clearance rates between functional activity and immunological measurements.
Impact:
- Findings highlight the critical role of AT III in mediating heparin's anticoagulant activity, suggesting that AT III levels should be monitored and supplemented when necessary.
- AT III substitution demonstrates potential for improving DIC management by reducing coagulation duration, although further studies are needed to confirm survival benefits.
- Simultaneous administration of AT III and heparin did not further shorten DIC duration but increased the risk of bleeding complications.